Liu W - Search Results

1

Downregulation of circ-STK39 suppresses pancreatic cancer progression by sponging mir-140-3p and regulating TRAM2-mediated epithelial-mesenchymal transition.

Li C, Cai J, Liu W, Gao Z, Li G. Li C, et al. Among authors: liu w. Apoptosis. 2023 Aug;28(7-8):1024-1034. doi: 10.1007/s10495-023-01813-9. Epub 2023 Apr 11. Apoptosis. 2023. PMID: 37041422

2

Peptide Transporter 1-Mediated Dipeptide Transport Promotes Hepatocellular Carcinoma Metastasis by Activating MAP4K4/G3BP2 Signaling Axis.

Song F, Zhang Z, Liu W, Xu T, Hu X, Wang Q, Zhang W, Ge L, Zhang C, Hu Q, Qin H, Zhang S, Ren X, Fan W, Zhang Y, Huang P. Song F, et al. Among authors: liu w. Adv Sci (Weinh). 2024 Jun;11(24):e2306671. doi: 10.1002/advs.202306671. Epub 2024 Apr 19. Adv Sci (Weinh). 2024. PMID: 38639383 Free PMC article.

3

Exosomal circRNAs in cancer: Implications for therapy resistance and biomarkers.

Lin Z, Ji Y, Zhou J, Li G, Wu Y, Liu W, Li Z, Liu T. Lin Z, et al. Among authors: liu w, liu t. Cancer Lett. 2023 Jul 10;566:216245. doi: 10.1016/j.canlet.2023.216245. Epub 2023 May 27. Cancer Lett. 2023. PMID: 37247772 Review.

4

Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma.

Liu W, Hu J, Zhou K, Chen F, Wang Z, Liao B, Dai Z, Cao Y, Fan J, Zhou J. Liu W, et al. Onco Targets Ther. 2017 Aug 1;10:3843-3851. doi: 10.2147/OTT.S140062. eCollection 2017. Onco Targets Ther. 2017. PMID: 28814883 Free PMC article.

5

Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma.

Zhou KQ, Liu WF, Yang LX, Sun YF, Hu J, Chen FY, Zhou C, Zhang XY, Peng YF, Yu L, Zhou J, Fan J, Wang Z. Zhou KQ, et al. Hepatobiliary Surg Nutr. 2019 Dec;8(6):582-596. doi: 10.21037/hbsn.2019.03.14. Hepatobiliary Surg Nutr. 2019. PMID: 31929985 Free PMC article.

6

The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma.

Pan JJ, Ge YS, Xu GL, Jia WD, Liu WF, Li JS, Liu WB. Pan JJ, et al. J Cancer Res Clin Oncol. 2013 Jun;139(6):1043-54. doi: 10.1007/s00432-013-1415-3. Epub 2013 Mar 23. J Cancer Res Clin Oncol. 2013. PMID: 23525579

7

Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1.

Hu J, Liu WF, Zhang XY, Shi GM, Yang XR, Zhou KQ, Hu B, Chen FY, Zhou C, Lau WY, Fan J, Wang Z, Zhou J. Hu J, et al. Hepatol Int. 2023 Oct;17(5):1265-1278. doi: 10.1007/s12072-023-10527-8. Epub 2023 Apr 28. Hepatol Int. 2023. PMID: 37115456

8

PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection.

Liao BY, Wang Z, Hu J, Liu WF, Shen ZZ, Zhang X, Yu L, Fan J, Zhou J. Liao BY, et al. Tumour Biol. 2016 Mar;37(3):2987-98. doi: 10.1007/s13277-015-4085-8. Epub 2015 Sep 28. Tumour Biol. 2016. PMID: 26415733

9

Low expression of exosomal miR-150 predicts poor prognosis in colorectal cancer patients after surgical resections.

Zhang Y, Liu WS, Zhang XY, Tong HX, Yang H, Liu WF, Fan J, Zhou J, Hu J. Zhang Y, et al. Carcinogenesis. 2022 Nov 23;43(10):930-940. doi: 10.1093/carcin/bgac059. Carcinogenesis. 2022. PMID: 35767307

10

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients.

Song Y, Zhang Q, Cai Q, Song Y, Zhang L, He P, Wang L, Hirata J, Musick L, Deng R, Liu W, Wang X, Zhu J. Song Y, et al. Among authors: liu w. J Cancer Res Ther. 2024 Dec 1;20(7):2133-2140. doi: 10.4103/jcrt.jcrt_269_24. Epub 2025 Jan 10. J Cancer Res Ther. 2024. PMID: 39792424

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59,677 results

Search Page

Filters